Want to see RAPP full AI Analyst Report?
RAPP Stock Chart & Stats
$52.50
$1.42(3.49%)
At close: 4:00 PM EDT
$52.50
$1.42(3.49%)
Day’s Range― - ―
52-Week Range$23.75 - $52.93
Previous CloseN/A
Volume230.44K
Average Volume (3M)410.33K
Market Cap
$1.45B
Enterprise Value$1.55B
Total Cash (Recent Filing)$436.08M
Total Debt (Recent Filing)$10.11M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Nov 05, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding47,978,287
10 Day Avg. Volume359,860
30 Day Avg. Volume410,330
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue77.61
Enterprise Value/Gross Profit77.61
Enterprise Value/Ebitda-10.46
Forecast
1Y Price Target
$62.33Price Target Upside18.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$20.00M
Bulls Say, Bears Say
Bulls Say
High Gross MarginThe approximately 96% gross margin indicates that the company’s emerging revenue has attractive underlying economics once products or partnerships begin generating sales. If this margin profile persists, future revenue growth could contribute meaningful gross profit to support continued development and commercialization.
Low LeverageVery low leverage gives Rapport greater financial flexibility than a heavily debt-funded development company. Limited debt reduces interest and refinancing pressure, allowing more of its capital base to remain available for research, clinical programs, and other long-term operating priorities.
Emerging Revenue BaseThe emergence of $20.0M in trailing revenue provides an initial indication that Rapport is beginning to convert development activity into economic activity. Although still early, this transition can broaden funding options and establish a base from which future partnered or product-related revenue may develop.
Bears Say
Deep Operating LossesRapport remains far from self-sustaining profitability, with operating expenses and research investment substantially exceeding its nascent revenue base. Persistent losses reduce internal funding capacity and mean that successful clinical and commercial progress is needed before the business can support itself from operations.
Substantial Cash BurnLarge recurring cash outflows show that reported losses are translating into substantial real cash consumption rather than being mainly non-cash accounting effects. Continued burn increases the importance of financing access and can constrain the pace or breadth of development programs if capital conditions worsen.
Capital-Raising DependenceReliance on external capital is a structural feature of Rapport’s current model because it does not typically generate recurring revenue from marketed products. Repeated financing needs can dilute existing holders and leave long-term execution dependent on continued investor support and funding availability.
Rapport Therapeutics, Inc. News
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $23.75 and its highest was $52.93 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $1.45B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 22 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Aug 05, 2026. The company reported -$1.19 earnings per share for the quarter, missing the consensus estimate of -$0.963 by -$0.227.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -1.21.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 47,978,287 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$1.19 in its last earnings report, missing expectations of -$0.963. Following the earnings report the stock price went up 0.569%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.33 (18.73% Upside)
$62.33 (18.73% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 197.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.77%
12-Months-Change
Fundamentals
Return on Equity
-29.02%
Trailing 12-Months
Asset Growth
60.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$62.33
▲(18.73% Upside)
Technical Analysis
Assembly Biosciences
―
Stoke Therapeutics
―
Alto Neuroscience, Inc.
―
MapLight Therapeutics, Inc.
―
Seaport Therapeutics, Inc.
―
Ownership Overview
22.31% Insiders
24.32% Mutual Funds
29.16% Other Institutional Investors
15.25% Public Companies and
Individual Investors